IP Library Granted Patent US 8,367,628
Granted Patent B2
US 8,367,628 · App. 12/085,893 · Granted Feb 5, 2013

Amphoteric liposome formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,628
App. No.
12/085,893
Granted
Feb 5, 2013
Kind
B2
Abstract

The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.

Claims (21)

1. A composition comprising an amphoteric liposome comprising

(i) a DNAi oligonucleotide comprising SEQ ID NOs: 1250 or 1251 or the complements thereof;

(ii) a mixture of lipid components comprising

POPC, DOPE, MoChol, and CHEMS in a molar ratio of POPC/DOPE/MoChol and CHEMS of about 6/24/47/23.

2. The composition of claim 1 , wherein the molar ratio of POPC/DOPE/MoChol/CHEMS is 6/24/47/23.

3. The composition of claim 1 , wherein the amphoteric liposomes comprise a size between about 50 and 500 nm.

4. The composition of claim 1 , wherein the amphoteric liposome comprises a size between about 80 and 200 nm.

5. The composition of claim 1 , wherein the amphoteric liposome has a DNAi oligonucleotide concentration of at least 2 mg/ml at a lipid concentration of about 100 mM or less.

6. The composition of claim 1 , wherein the DNAi oligonucleotide comprises SEQ ID NOs: 1250 or 1251.

7. The composition of claim 1 , wherein the DNAi oligonucleotide comprises SEQ ID NO: 1251.

8. A method comprising

(a) providing the composition of claim 1 , and

(b) introducing the composition into a cell or animal capable of expressing the bcl-2 gene.

9. The method of claim 8 , wherein introducing the composition results in a reduction of proliferation of the cell, or induces cell death.

10. The method of claim 8 , wherein the cell is a cancer cell.

11. The method of claim 8 , wherein the animal is a human.

12. The method of claim 8 , wherein the composition is introduced to the animal by one or more routes of administration selected from topical, pulmonary, intraocular, intranasal, parenteral, and a medical device.

13. The method of claim 8 , wherein the cell is in cell culture.

14. The method of claim 8 , further comprising the step of introducing a chemotherapy agent to the cell or animal.

15. The method of claim 8 , wherein said animal has a cancer which is selected from pancreatic cancer, colon cancer, breast cancer, bladder cancer, lung cancer, leukemia, prostate cancer, lymphoma, ovarian cancer and melanoma.

16. A pharmaceutical composition comprising an amphoteric liposome and a DNAi oligonucleotide comprising SEQ ID NOs:1251 or 1250 wherein the liposome comprises POPC, DOPE, MoChol and CHEMS in the molar ratio of POPC/DOPE/MoChol/CHEMS of 6/24/47/23.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2020
From: NOVOSOM VERWALTUNGS GMBH
To: BIONTECH PROTEIN THERAPEUTICS GMBH
Reel/Frame 052957/0839 →
CHANGE OF NAME Recorded Jun 16, 2020
From: BIONTECH PROTEIN THERAPEUTICS GMBH
To: BIONTECH DELIVERY TECHNOLOGIES GMBH
Reel/Frame 052958/0096 →
CHANGE OF NAME Recorded Oct 27, 2015
From: NOVOSOM AG
To: NOVOSOM VERWALTUNGS GMBH
Reel/Frame 036894/0148 →
RELEASE OF SECURITY INTEREST Recorded Apr 14, 2014
From: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
To: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
Reel/Frame 032685/0158 →
SECURITY AGREEMENT Recorded May 13, 2013
From: MARINA BIOTECH, INC.; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: MONSANTO COMPANY
Reel/Frame 030401/0461 →
SECURITY AGREEMENT Recorded Feb 15, 2012
From: MARINA BIOTECH, INC; CEQUENT PHARMACEUTICALS, INC.; MDRNA RESEARCH, INC.
To: GENESIS CAPITAL MANAGEMENT, LLC, AS AGENT
Reel/Frame 027712/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2009
From: ENDERT, GEROLD; HERZOG, NATALIE; KERWITZ, YVONNE; PANZNER, STEFFEN
To: NOVOSOM AG
Reel/Frame 023382/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2009
From: GOODWIN, NEAL CLIFFORD; RODRIGUEZA, WENDI
To: PRONAI THERAPEUTICS, INC.
Reel/Frame 023382/0103 →